We develop genetic technology.
Aging is a bug. We fix it.
Research and Development headquarters and bioproduction center. These facilities are where experimental protocols, preclinical validation, and biotechnological production necessary for the advancement of our programs are carried out.
Network of scientific collaborations and legal affiliations. This node establishes links with academic institutions, researchers, and international legal structures that support the development and expansion of our operations.
Administrative headquarters and clinical planning hub. Manages the corporate structure and the design of future clinical trial programs.
RenovaCode Therapeutics is founded. During its initial research phase, ICER is developed and its technical feasibility is demonstrated, establishing the basis for biological age reversal as an executable process.
ICER is formally presented at the International Congress of Aging and Gerontology, marking its first public scientific disclosure to the longevity research community.
RenovaCode Therapeutics is selected among the world’s top 250 emerging companies by the Saudi Government, recognizing the disruptive potential of its technological approach.
Following validation and recognition, RenovaCode enters the operational development phase, initiating structured research programs, infrastructure expansion, and the translation of ICER into scalable experimental pipelines.